Scarica l'app Stockscreener
6.14
16.07%
0.85
Dopo l'orario di chiusura:
6.15
0.01
+0.16%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$5.29
Aprire:
$5.3
Volume 24 ore:
6.75M
Relative Volume:
2.97
Capitalizzazione di mercato:
$337.39M
Reddito:
$3.64M
Utile/perdita netta:
$-87.37M
Rapporto P/E:
-1.4939
EPS:
-4.11
Flusso di cassa netto:
$-86.46M
1 W Prestazione:
+18.99%
1M Prestazione:
+42.79%
6M Prestazione:
+3.72%
1 anno Prestazione:
+106.73%
Intervallo 1D:
$5.15
$6.29
Intervallo di 1 settimana:
$4.86
$6.29
Portata 52W:
$2.10
$9.10
Verastem Inc Stock (VSTM) Company Profile
Nome
Verastem Inc
Settore
Industria
Telefono
(781) 292-4200
Indirizzo
117 KENDRICK STREET, NEEDHAM, MA
Confronta VSTM con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VSTM
Verastem Inc
|
6.14 | 290.68M | 3.64M | -87.37M | -86.46M | -4.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Verastem Inc Stock (VSTM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-10 | Iniziato | Jefferies | Buy |
| 2025-03-24 | Reiterato | H.C. Wainwright | Buy |
| 2024-12-31 | Reiterato | BTIG Research | Buy |
| 2024-09-30 | Iniziato | Guggenheim | Buy |
| 2023-11-21 | Ripresa | BTIG Research | Buy |
| 2023-09-27 | Iniziato | B. Riley Securities | Buy |
| 2023-06-15 | Aggiornamento | Mizuho | Neutral → Buy |
| 2022-09-07 | Ripresa | Alliance Global Partners | Buy |
| 2022-04-29 | Ripresa | Cantor Fitzgerald | Overweight |
| 2022-04-14 | Iniziato | RBC Capital Mkts | Outperform |
| 2022-03-09 | Iniziato | Truist | Buy |
| 2021-07-01 | Iniziato | Alliance Global Partners | Buy |
| 2021-05-24 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2019-06-20 | Downgrade | BTIG Research | Buy → Neutral |
| 2019-05-10 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2018-07-13 | Iniziato | BTIG Research | Buy |
| 2018-05-02 | Iniziato | Seaport Global Securities | Buy |
| 2018-03-08 | Iniziato | B. Riley FBR, Inc. | Buy |
| 2017-09-07 | Reiterato | H.C. Wainwright | Buy |
| 2017-04-13 | Iniziato | Oppenheimer | Outperform |
| 2017-03-24 | Reiterato | H.C. Wainwright | Buy |
| 2015-09-29 | Downgrade | Cantor Fitzgerald | Buy → Hold |
| 2015-09-29 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2015-09-29 | Downgrade | Jefferies | Buy → Hold |
| 2015-09-29 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2015-09-28 | Downgrade | Mizuho | Buy → Neutral |
| 2015-09-28 | Downgrade | ROTH Capital | Buy → Neutral |
| 2015-09-09 | Iniziato | Raymond James | Strong Buy |
| 2015-05-12 | Reiterato | UBS | Buy |
| 2015-04-08 | Iniziato | H.C. Wainwright | Buy |
| 2015-01-23 | Reiterato | ROTH Capital | Buy |
| 2014-07-08 | Ripresa | Oppenheimer | Perform |
| 2014-02-11 | Iniziato | Mizuho | Buy |
Mostra tutto
Verastem Inc Borsa (VSTM) Ultime notizie
What drives Verastem Inc. stock priceUnstoppable profit momentum - PrintWeekIndia
FDA Grants Fast Track Designation to VS-7375 for KRAS G12D-Mutated Pancreatic Cancer - Targeted Oncology
Verastem Inc. Stock Analysis and ForecastRapid capital growth - PrintWeekIndia
Verastem Oncology Granted Fast Track Designation for VS-7375 for the Treatment of KRAS G12D-mutated Locally Advanced or Metastatic Pancreatic Cancer - BioSpace
What analysts say about Verastem Inc. stockFree Market Dynamics Reports - Autocar Professional
Is Verastem Inc. a good long term investmentAccelerated earnings growth - Autocar Professional
Verastem’s Phase 3 Study Update: A Potential Game-Changer in Ovarian Cancer Treatment - TipRanks
Verastem's Fast-Track KRAS G12D Inhibitor: A Strategic Play in a High-Unmet-Need Oncology Market - AInvest
Verastem Oncology gets FDA fast track status for cancer drug - Seeking Alpha
Verastem Oncology’s VS-7375 Granted Fast Track Designation by the FDA - Contract Pharma
FDA grants fast track designation to Verastem’s pancreatic cancer drug By Investing.com - Investing.com Canada
High‑Growth Oncology Market Projected For US$900bn in Revenue Despite Policy Headwinds - The Malaysian Reserve
High‑Growth Oncology Market Projected For US$900bn in Revenue Despite Policy Headwinds - Benzinga
(VSTM) Proactive Strategies - news.stocktradersdaily.com
Verastem’s Promising KRAS G12D Inhibitor Study: A Potential Game-Changer in Cancer Treatment - TipRanks
Verastem: The Market Is Ignoring The Progress (NASDAQ:VSTM) - Seeking Alpha
Why Verastem Inc. stock attracts strong analyst attentionDaily Trade Opportunity - beatles.ru
What makes Verastem Inc. stock price move sharplyEntry Level Low Risk Picks - Newser
How Verastem Inc. stock performs during market volatilityFast Moving Stock Alerts - Newser
Avutometinib-Defactinib: A New Standard in Precision Oncology? - AInvest
Verastem’s avutometinib combination shows 31% ORR in ovarian cancer trial - Yahoo Finance
Verastem Oncology's Breakthrough in LGSOC: A New Standard of Care with Substantial Upside Potential - AInvest
Verastem’s cancer drug shows 31% response rate in ovarian cancer trial By Investing.com - Investing.com Canada
Verastem stock rises after LGSOC treatment data published in medical journal - Investing.com
Verastem stock rises after LGSOC treatment data published in medical journal By Investing.com - Investing.com South Africa
Verastem Oncology Announces Publication of the Primary Results from the Phase 2 RAMP 201 Trial of Avutometinib in Combination with Defactinib in Patients with Recurrent Low-Grade Serous Ovarian Cancer in the Journal of Clinical Oncology - Yahoo Finance
Verastem Inc Azioni (VSTM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Verastem Inc Azioni (VSTM) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Calkins Daniel | Chief Financial Officer |
Jun 20 '25 |
Sale |
5.13 |
4,110 |
21,084 |
109,945 |
| Calkins Daniel | Chief Financial Officer |
Jun 23 '25 |
Sale |
4.71 |
25 |
118 |
109,920 |
0.97%
0.22%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):